76 years old | 0
woman | 0
metastatic lung adenocarcinoma | -2160
palliative chemoimmunotherapy | -2160
fevers | 0
dyspnea | 0
cough | 0
invasive ductal carcinoma of the right breast | -5520
lumpectomy | -5520
aromatase inhibitor | -5520
20 pack-year tobacco use history | -306240
ceased smoking 35 years ago | -306240
recently traveled to the Southwest United States | -720
no history of chest radiation | 0
hypoxemia on exertion | -2160
right upper lobe mass | -2160
lung metastases | -2160
liver metastases | -2160
biopsy of the lung | -2160
biopsy of the liver | -2160
metastatic adenocarcinoma consistent with lung origin | -2160
no actionable mutations on standard tumor molecular profiling | -2160
carboplatin | -2160
pemetrexed | -2160
pembrolizumab | -2160
administered intravenously every 21 days | -2160
stable disease | -1080
fevers (midway through the fourth cycle) | -1080
dyspnea on exertion (midway through the fourth cycle) | -1080
cough (midway through the fourth cycle) | -1080
CT angiogram of the chest | 0
no pulmonary embolism | 0
confluent regions of consolidation in the lungs bilaterally | 0
significantly worse on the left | 0
small left pleural effusion | 0
bilateral cavitary lung lesions | 0
admitted to the intensive care unit | 0
severe hypoxemic respiratory failure | 0
PaO2/FiO2 ratio of 87 | 0
broad-spectrum antibiotics | 0
worsening hypoxemia on day three | 72
endotracheal intubation | 72
mechanical ventilation | 72
positive end-expiratory pressure titrated | 72
lung protective ventilation utilizing a low tidal volume strategy | 72
bronchoscopy on day three | 72
thin secretions in the left lower lobe | 72
bronchoalveolar lavage studies | 72
neutrophilic predominance (70%) | 72
neutrophilic predominance (54%) | 72
negative gram stain | 72
negative bacterial culture | 72
negative viral culture | 72
negative legionella culture | 72
negative fungal culture | 72
negative nocardia culture | 72
negative acid-fast bacteria culture | 72
negative Aspergillus galactomannan antigen | 72
negative blood markers of infection | 72
negative urine markers of infection | 72
transthoracic echocardiogram | 72
mild symmetric left ventricular hypertrophy | 72
normal right ventricular size | 72
normal right ventricular systolic function | 72
no significant valvular disease | 72
no signs of increased filling pressures | 72
no atrial septal defect | 72
deferred lung biopsy | 72
immune checkpoint inhibitor pneumonitis suspected | 72
intravenous methylprednisolone (2 mg/kg/day) | 72
significant desaturations on day nine | 216
FiO2 of 0.8 | 216
positive end-expiratory pressure of 10 cmH2O | 216
negative total body fluid balance | 216
steroid-refractory pembrolizumab-induced pneumonitis | 216
intravenous immunoglobulin (IVIg) | 216
IVIg administered on days 9â€“13 | 216
rapid and significant clinical improvement | 216
radiographic improvement | 216
successful extubation on day 12 | 288
repeat chest CT imaging on day 12 | 288
marked improvement in severe interstitial abnormality | 288
organizing phase of acute lung injury | 288
clinical response to immunomodulatory therapy | 288
transitioned to prednisone (1 mg/kg/day) | 336
supplemental oxygen requirement decreased | 336
weaned to an oxymizer device | 336
discharged on day 23 | 552
oxygen needs decreased to 1.5 L per minute | 1344
improved exercise tolerance | 1344
prednisone decreased to 0.5 mg/kg/day | 1344
slow taper over 2 months | 1344
re-staging CT of the torso performed six weeks after admission | 1008
continued improvement of the left-sided infiltrate | 1008
remaining bilateral subpleural interstitial fibrotic abnormality | 1008
stable malignant disease burden | 1008
